DK1863849T3 - Bekæmpelse af gnavere - Google Patents

Bekæmpelse af gnavere

Info

Publication number
DK1863849T3
DK1863849T3 DK06709799.8T DK06709799T DK1863849T3 DK 1863849 T3 DK1863849 T3 DK 1863849T3 DK 06709799 T DK06709799 T DK 06709799T DK 1863849 T3 DK1863849 T3 DK 1863849T3
Authority
DK
Denmark
Prior art keywords
rodents
fighting
fighting rodents
Prior art date
Application number
DK06709799.8T
Other languages
English (en)
Inventor
Patricia Jane Cayley
Andrew John Dinsmore
Fergus Gerard Paul Earley
Claire Judith Anne Sadler
Jason Leigh Vincent
Original Assignee
Syngenta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0505054A external-priority patent/GB0505054D0/en
Priority claimed from GB0600719A external-priority patent/GB0600719D0/en
Application filed by Syngenta Ltd filed Critical Syngenta Ltd
Application granted granted Critical
Publication of DK1863849T3 publication Critical patent/DK1863849T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Catching Or Destruction (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK06709799.8T 2005-03-11 2006-02-17 Bekæmpelse af gnavere DK1863849T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0505054A GB0505054D0 (en) 2005-03-11 2005-03-11 Antibodies
GB0600719A GB0600719D0 (en) 2006-01-13 2006-01-13 Pest control
PCT/GB2006/000562 WO2006095128A2 (en) 2005-03-11 2006-02-17 Rodent pest control

Publications (1)

Publication Number Publication Date
DK1863849T3 true DK1863849T3 (da) 2011-08-08

Family

ID=36216798

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06709799.8T DK1863849T3 (da) 2005-03-11 2006-02-17 Bekæmpelse af gnavere

Country Status (17)

Country Link
US (1) US8349328B2 (da)
EP (1) EP1863849B1 (da)
JP (1) JP5032458B2 (da)
AR (1) AR052502A1 (da)
AT (1) ATE507245T1 (da)
AU (1) AU2006221823B2 (da)
BR (1) BRPI0608838A2 (da)
CA (1) CA2599465A1 (da)
DE (1) DE602006021552D1 (da)
DK (1) DK1863849T3 (da)
GT (1) GT200600108A (da)
MX (1) MX2007010899A (da)
MY (1) MY149858A (da)
PL (1) PL1863849T3 (da)
PT (1) PT1863849E (da)
TW (1) TWI396695B (da)
WO (1) WO2006095128A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0721937D0 (en) 2007-11-08 2007-12-19 Secr Defence Rodenticide
ITBO20090012A1 (it) * 2009-01-15 2010-07-16 Vincenza Dolo Composizione biocida e suo uso.
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
ITBO20120094A1 (it) * 2012-02-28 2013-08-29 Vincenza Dolo Composizione biocida
GB201221069D0 (en) * 2012-11-23 2013-01-09 Univ Reading Control method
AU2014217917A1 (en) * 2013-02-18 2015-09-03 University Of Maryland, Baltimore Peptide additives for enhancing acceptance and ingestion of edibles by rodents and uses thereof
MX2018014382A (es) * 2016-05-23 2019-08-12 Gries Gerhard Atrayentes para roedores.
EP3415010A1 (en) * 2017-06-13 2018-12-19 Agrosavfe Nv Insect-controlling polypeptides and methods

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2633834A1 (de) * 1975-08-19 1977-03-03 Lipha Nagetierbekaempfungsmittel und dessen verwendung
US4851332A (en) 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
BE1000534A5 (fr) * 1987-05-15 1989-01-17 Billen E Ets Sprl Composition pour l'extermination d'animaux rongeurs.
US5290914A (en) * 1988-04-28 1994-03-01 Mycogen Corporation Hybrid diphtheria-B.t. pesticidal toxins
AU631129B2 (en) * 1988-06-17 1992-11-19 E.I. Du Pont De Nemours And Company Pesticidal compositions
US6326467B1 (en) * 1989-02-23 2001-12-04 Colorado State University Research Foundation Hormone-recombinant toxin compounds and methods for using same
US5237051A (en) * 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
US5849870A (en) 1993-03-25 1998-12-15 Novartis Finance Corporation Pesticidal proteins and strains
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
TW585921B (en) * 1997-07-10 2004-05-01 Res Dev Foundation Species specific monoclonal antibodies and phage displayed Fab and scFV fragments for fragments for targeted destruction of imported fire ants
ATE535154T1 (de) 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
US6492498B1 (en) * 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
WO2001058955A1 (en) 2000-02-10 2001-08-16 Research Development Foundation Targeted destruction of pests
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
GB0015935D0 (en) * 2000-06-30 2000-08-23 Univ Sheffield Vaccine
EP1433793A4 (en) * 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US20050009188A1 (en) * 2002-09-19 2005-01-13 Kitto G. Barrie Animal immunocontraceptives expressed in plants and uses thereof

Also Published As

Publication number Publication date
ATE507245T1 (de) 2011-05-15
MY149858A (en) 2013-10-31
GT200600108A (es) 2006-10-25
DE602006021552D1 (de) 2011-06-09
EP1863849B1 (en) 2011-04-27
EP1863849A2 (en) 2007-12-12
JP2008532986A (ja) 2008-08-21
WO2006095128A3 (en) 2006-11-30
US8349328B2 (en) 2013-01-08
AU2006221823A1 (en) 2006-09-14
TWI396695B (zh) 2013-05-21
CA2599465A1 (en) 2006-09-14
AR052502A1 (es) 2007-03-21
JP5032458B2 (ja) 2012-09-26
MX2007010899A (es) 2007-12-06
BRPI0608838A2 (pt) 2010-02-02
PL1863849T3 (pl) 2011-09-30
TW200643031A (en) 2006-12-16
US20100158892A1 (en) 2010-06-24
WO2006095128A2 (en) 2006-09-14
PT1863849E (pt) 2011-05-10
AU2006221823B2 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
ATE477250T1 (de) Cyanoanthranilamidinsektizide
DK1965646T3 (da) Herbicid sammensætning
DK2449883T3 (da) Herbicidsammensætninger
ATE445999T1 (de) Landwirtschaftliches gerät
DK1949552T3 (da) Konfigurering af ekkoundertrykkelse
DE602006014304D1 (de) Sprühvorrichtung
DE602006002695D1 (de) Mähwerksgehäuse
DE602006015684D1 (de) Sprühvorrichtung
DE602006014297D1 (de) Sprühvorrichtung
BRPI0818261A2 (pt) Combinação herbicida
AT502689A3 (de) Erntemaschine
DE602006007197D1 (de) Kamera
ATE423466T1 (de) Herbizidzusammensetzung
DK1998622T3 (da) Herbicidsammensætning
DK1863849T3 (da) Bekæmpelse af gnavere
BRPI0716197A2 (pt) Fungicidas
DK1928245T3 (da) Herbicidsammensætning
DE112005001784A5 (de) Geruchsverschluss
AT502917A3 (de) Erntemaschine
DE602006019686D1 (de) Mähmaschine
CU23826B1 (es) Composición herbicida
AT502690A3 (de) Erntemaschine
AT501972A3 (de) Mähmaschine
ITPD20050018A1 (it) Composizione insetticida
BRPI0818880A2 (pt) Combinação herbicida